SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More
Pfizer
Pfizer, Syapse Partner on Oncology Precision Medicine Using Real-World Evidence (RWE)
Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.Syapse NetworkThe Syapse Network enables health systems and their providers to learn
Read More
Pfizer, McKesson, Others Join MediLedger’s Blockchain Project Working Group
Leading life sciences and healthcare companies Pfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have joined the MediLedger Project Contracting and Chargebacks working group, a second working group running in parallel to the ongoing DSCSA working group started in 2017. MediLedger is an initiative of Chronicled, Inc., a San Francisco-based technology company, that builds blockchain-powered ecosystems and supply chain solutions.Network VisionMediLedger uses
Read More
Digital Twin Technology: Should Healthcare Jump on the Bandwagon?
While healthcare is known for not jumping to conclusions very fast when investing in new technology, the industry starts to pick up the pace. Such “newcomers” as blockchain, IoT, VR, and AR get a well-deserved appraisal and become an integral part of next-gen custom healthcare software aimed at supporting personalized treatment and predictable patient outcomes across a wide range of conditions.
We anticipate that the digital twin technology has good chances to become the next addition to the
Read More
Pfizer & Concerto HealthAI Team Up on Precision Oncology Collaboration
Concerto HealthAI announced a deal
with Pfizer, through which Pfizer will
harness Concerto HealthAI’s eurekaHealth AI platform
and real-world data (RWD) to help identify new and more precise treatment
options as well as accelerate completion times for various outcomes studies. Concerto
HealthAI is comprised of the leading healthcare data scientists, health
economists, epidemiologists, and AI software engineers to advance flexible and
increasingly enterprise grade solutions for advancing RWE into
Read More
TriNetX Acquires European Clinical Data Network InSite
TriNetX, a global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE) has acquired Belgium-based Custodix NV and its InSite network. InSite network is a European-based provider of services for clinical trial design, patient feasibility, and enabling workflow for patient recruitment. Financial details of the acquisition were not disclosed.
InSite Clinical Data Network Background
The InSite platform is an
Read More
Ochsner Health and Pfizer to Develop Innovative Models for Clinical Trials
Ochsner Health System and Pfizer Inc, today announced it has entered into a multi-year strategic alliance to develop innovative models for clinical trials that will explore ways to enhance the clinical trial experience and ease participation in clinical research for both patients and healthcare professionals. Through its innovation lab, innovationOchsner (iO), in partnership with Oschner Research, the alliance aims to create faster, improved access and connectivity to clinical trials for
Read More
GlaxoSmithKline and Pfizer Form New Consumer Health Joint Venture
GlaxoSmithKline and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture provides a unique opportunity to accelerate GSK’s strategy and create substantial value for shareholders. GlaxoSmithKline has reached an agreement with Pfizer Inc to combine their consumer health businesses into a consumer health Joint Venture, with combined sales of approximately $12.7B. As part of the agreement, GSK will have a majority controlling equity interest of 68% and Pfizer will have an equity
Read More
Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations
SpringWorks Therapeutics, a new Pfizer spin-off launched as a way to advance investigational drug therapies that may hold significant promise for underserved patients has raised $103 million in funding in Series A funding. The Series A round was led by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer and LifeArc (formerly known as MRC Technology). SpringWorks Therapeutics’ collaborative business model is designed to deliver both social and financial returns via
Read More
Pfizer Pumps $9M Into Swedish Digital Health Firm AMRA to Abolish Outdated BMI with Precision Measurements
Pharmacy giant Pfizer has invested $9 million in AMRA, a Swedish digital health firm that transforms MR images into precise body composition measurements through its venture capital arm, Pfizer Venture Investments (PVI) co-led by Novo Seeds with participation from Industrifonden. The company plans to utilize the funding to further build its global presence and grow its network among researchers and pharmaceutical companies.Additionally, it has plans to establish a US subsidiary and expand its
Read More
